Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 2018

View Archived Issues

Patient enrollment ongoing in first-in-human trial of PF-06939926

Sun Biopharma initiates first-line combination study of SBP-101 with gemcitabine and nab-paclitaxel

FDA gives fast track status to Ensysce's PF-614

Zika virus vaccine candidate from Takeda obtains FDA fast track designation

Trial results support safety and activity of carotuximab + sorafenib in hepatocellular carcinoma

ASPH marker possibly useful for CRC screening

EMA committee recommends approval of Lamzede for alpha-mannosidosis

United Neuroscience to develop vaccine to prevent chronic traumatic encephalopathy

GSK-2256098/trametinib combination lacks activity in phase II PDAC study

Innate Pharma and MedImmune collaborate to study IPH-5401 with durvalumab

Chinese authorities approve clinical trials of ZKAB-001

First patient with DLBCL enrolled in phase II study of Cellectar's CLR-131

FDA awards RMAT designation to Abeona Therapeutics' EB-101

Regeneron studies long-term safety and efficacy of evinacumab in patients with HoFH

BL-8040 therapy impacts immune cell populations in pancreatic cancer patients

FDA issues complete response letter for Linhaliq NDA

Pfizer files for approval of lorlatinib in Japan

Bristol-Myers Squibb presents novel ROCK inhibitors

Leo Pharma divulges RORG ligands for psoriasis

Almac Discovery discloses new Wee1 inhibitors

Duke University patents APC-containing vaccines for cancer

Ibentrus identifies new fusion proteins for cancer

ProMetic Life Sciences finalizes design of phase III study of PBI-4050 in IPF

FDA accepts revefenacin NDA

Johnson & Johnson reviews pipeline progress of fourth quarter 2017

Phase I data presented for JCAR-017 in B-NHL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...